Merck & Co., Inc. $MRK Shares Sold by Community Trust & Investment Co.

Community Trust & Investment Co. cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 11.0% during the second quarter, Holdings Channel reports. The firm owned 34,265 shares of the company’s stock after selling 4,216 shares during the quarter. Community Trust & Investment Co.’s holdings in Merck & Co., Inc. were worth $4,403,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. High Note Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Insiders Place Their Bets

In other news, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 86,553 shares of company stock valued at $11,177,945 in the last three months. Insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MRK. CICC Research started coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Guggenheim boosted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Finally, Barclays raised their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Thirteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $134.56.

Merck & Co., Inc. Stock Up 0.2%

Merck & Co., Inc. stock opened at $128.61 on Friday. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $317.64 billion, a PE ratio of 102.89, a P/E/G ratio of 5.53 and a beta of 0.19. The firm’s 50 day moving average price is $123.98 and its two-hundred day moving average price is $119.11.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter last year, the business posted $2.13 EPS. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.